Equity research analysts and forecasting platforms tracking CRISPR Therapeutics AG (CRSP) estimate that its average stock price throughout 2026 will range anywhere from approximately $72 up to a high-end consensus target near $167. These predictive valuations fluctuate depending on broader biotechnology sector sentiment, clinical trial execution milestones, and accelerating commercial sales data for its flagship gene-editing treatments.